Cantor Fitzgerald & Glancy Prongay & Murray
3 shared events · Importance 3 · Last updated Sep 09, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Cantor Fitzgerald: Cantor Fitzgerald downgraded ADMA Biologics stock from Overweight to Neutral following the Culper Research report.
Glancy Prongay & Murray: Glancy Prongay & Murray is involved in the class action, reminding investors of the deadline and seeking lead plaintiff roles. It stands to gain from the litigation.
Jun 14, 2026 · 294 articles
Regulatory
Cantor Fitzgerald: Analyst firm that published a negative note on the FDA briefing documents.
Glancy Prongay & Murray: Filed a class action lawsuit against Capricor.
Jul 27, 2026 · 305 articles
Regulatory
Cantor Fitzgerald: Cantor Fitzgerald analyst Kristen Kluska published an investor note stating the FDA briefing documents paint an ugly picture and raise concerns about the integrity of data collection, a view cited in the complaint.
Glancy Prongay & Murray: The firm announced the opportunity for investors with losses to lead the securities fraud class action before the September 28, 2026 deadline.
Aug 10, 2026 · 267 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Cantor Fitzgerald and Glancy Prongay & Murray interact across events, view sentiment trends, and discover connected entities.
Open Dashboard